Madrigal Pharmaceuticals, Inc. MDGL R2K
Company Overview
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 165.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $958.40M (+432.1% YoY); net profit $-288.28M.
- Trailing 12 Months Year-on-year growth — revenue +126.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 165.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 165.34% |
| 1 Year: | 126.80% |
Stock Price Performance
| 1 Year: | +67.84% |
| 6 Months: | +4.44% |
| 3 Months: | +2.13% |
| 1 Month: | +13.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.50 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 165.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDGL Madrigal Pharmaceuticals, Inc. R2K | 536.86 | -39.74 | $12.38B | 0.00% | -31.61% | -49.35% | 165.34% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 0 | 14.64M | 62.17M | 137.25M | 212.80M | 287.27M | 311.34M |
| Operating Income | -880.03K | -10.38M | -738.00K | -2.64M | -14.09M | -6.08M | -8.44M | -8.64M | -8.91M | -7.07M | -7.83M | -11.33M | -14.45M | -18.12M | -22.70M | -24.20M | -29.95M | -38.01M | -50.33M | -58.79M | -59.55M | -52.98M | -61.74M | -63.16M | -64.60M | -57.59M | -70.27M | -80.41M | -85.30M | -78.34M | -86.45M | -98.53M | -117.18M | -152.04M | -162.54M | -116.30M | -79.31M | -47.20M | -113.97M | -92.72M |
| Net Income | - | - | - | - | - | -6.00M | -8.35M | -8.36M | -8.45M | -6.36M | -6.46M | -8.51M | -11.47M | -15.08M | -19.70M | -21.43M | -27.74M | -36.13M | -49.02M | -57.96M | -59.12M | -52.55M | -61.65M | -63.10M | -64.55M | -57.52M | -70.73M | -81.20M | -85.91M | -76.90M | -85.80M | -98.74M | -112.19M | -147.54M | -151.97M | -106.96M | -73.24M | -42.28M | -114.19M | -94.39M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.32 | -3.72 | -3.79 | -3.78 | -3.36 | -4.14 | -4.75 | -4.98 | -4.23 | -4.69 | -5.34 | -5.68 | -7.38 | -7.10 | -4.92 | -2.61 | -1.50 | -4.01 | -3.25 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 147.00K | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180.13M | 958.40M |
| Operating Income | 79.30M | -36.90M | -45.43M | -60.94M | -87.56M | -83.95M | -3.23M | -25.22M | -32.06M | -40.68M | -94.97M | -206.67M | -242.48M | -293.57M | -380.50M | -497.88M | -300.10M |
| Net Income | 79.09M | -37.47M | -47.38M | -62.79M | -90.19M | -86.16M | -6.84M | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M |
| Diluted EPS | 2.32 | -0.93 | -1.00 | - | - | - | - | - | - | - | - | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 | -12.85 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 54.07M | 42.32M | 103.02M | 95.20M | 100.67M | 363.58K | 41.21M | 192.31M | 485.43M | 442.06M | 287.00M | 273.33M | 362.57M | 640.55M | 1.04B | 1.26B |
| Total Equity | -58.79M | 24.91M | 23.48M | 14.77M | 75.07M | 49.09M | -42.07M | -48.91M | 36.41M | 182.26M | 476.98M | 416.56M | 239.97M | 196.11M | 197.39M | 405.33M | 754.38M | 602.69M |
| Cash & Equivalents | 52.05M | 44.16M | 31.31M | 30.07M | 81.51M | 48.49M | 148.07K | 306.00K | 19.14M | 148.63M | 57.38M | 46.70M | 54.00M | 36.27M | 331.55M | 99.92M | 100.02M | 198.69M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 49.29M | 115.48M | 117.57M | 339.88M |
| Total Liabilities | - | - | 30.59M | 27.55M | 27.95M | 46.11M | 35.54M | 49.28M | 4.80M | 10.05M | 8.44M | 25.49M | 47.02M | 77.22M | 165.18M | 235.21M | 287.86M | 656.90M |
| Current Liabilities | - | - | 16.74M | 15.15M | 23.49M | 32.21M | 30.89M | 49.28M | 4.80M | 10.05M | 8.44M | 25.13M | 46.56M | 76.84M | 115.89M | 118.55M | 169.28M | 310.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | -17.61M | -22.32M | -25.51M | -41.62M | -157.56M | -183.92M | -224.86M | -324.23M | -455.57M | -189.55M |
| Investing Cash Flow | - | - | - | - | - | - | - | 21.99M | -22.01M | -380.08M | 30.71M | 159.78M | -5.05M | 206.69M | -502.52M | -274.39M | 32.32M |
| Financing Cash Flow | - | - | - | - | - | - | - | 14.45M | 173.81M | 314.33M | 235.00K | 5.09M | 171.24M | 313.45M | 595.12M | 735.06M | 255.98M |
| Capital Expenditure | -454.00K | -136.00K | -690.00K | -505.00K | -769.00K | -144.00K | -58.00K | -3.00K | -125.00K | -22.00K | -172.00K | -334.00K | -209.00K | -217.00K | -1.48M | -1.46M | -467.00K |
| Free Cash Flow | - | - | - | - | - | - | - | -17.61M | -22.44M | -25.53M | -41.80M | -157.90M | -184.13M | -225.07M | -325.71M | -457.03M | -190.02M |
| Share Buybacks | - | - | - | 32.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -41,456.5% | - | - | - | - | - | - | - | - | - | - | - | -276.4% | -31.3% |
| Net Margin % | - | - | - | -42,714.3% | - | - | - | - | - | - | - | - | - | - | - | -258.6% | -30.1% |
| ROE % | 317.5% | -159.6% | -320.7% | -83.6% | -183.7% | 204.8% | 14.0% | -72.5% | -17.1% | -6.9% | -20.2% | -84.3% | -123.3% | -149.6% | -92.2% | -61.8% | -47.8% |
| ROCE % | - | -98.8% | -167.2% | -76.6% | -139.0% | -120.3% | 6.6% | -69.3% | -17.6% | -8.5% | -22.8% | -86.0% | -123.4% | -119.0% | -72.9% | -57.0% | -31.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 9.29% | 2.14M | $1.14B |
| 2 | Janus Henderson Group PLC | 8.76% | 2.02M | $1.07B |
| 3 | RTW Investments LP | 8.65% | 1.99M | $1.06B |
| 4 | Avoro Capital Advisors LLC | 7.89% | 1.82M | $966.01M |
| 5 | Blackrock Inc. | 6.77% | 1.56M | $828.82M |
| 6 | PAULSON & CO. INC. | 6.04% | 1.39M | $739.68M |
| 7 | Vanguard Portfolio Management LLC | 3.65% | 841.14K | $446.90M |
| 8 | Vanguard Capital Management LLC | 3.59% | 827.14K | $439.47M |
| 9 | Wellington Management Group, LLP | 3.01% | 694.96K | $369.23M |
| 10 | State Street Corporation | 2.64% | 609.52K | $323.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDGL
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNMUpndU9GeUN6d1FMejJLT1dKazg3SWNXTkpwclc2OE13WUZZUlQwSi1vLWF5NkljTTZDNjFkZlB1N1VOTFRHX1NBSUdJSGVVVGtWa2E0eENnSzFJT1lXSEd1ejRibWV0V0dWemhDYUVaSm9IVVo1SGw1YzhUUWU1ZmdNOU5jTUxHcVNNM1…
New Rezdiffra patents extend Madrigal’s MASH IP into cirrhosis care - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPc29STHZXbGVnaWw2aFBET1AyS2VVOEZOcVR3NURBZVJNMm5xMDlFU0NzXzE3U0dxQ3ZiLXM2ZGUxU0JjZEFvRU5FeEVEdjZQTWswd1pGX2R1eUFXUXNrUm9IcUdDZ0VtOWlKcTdjMHZxeFNPWWd1R3k0ZVdESkhiODF4UnRDdUdqeTEtTj…
MDGL Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE15WGE0dktFa21RQWJ4cDZreE85LTlxbmJoRzNpRXBsZHNhS1dzcjI1TE82ODNlRGwwUUpoRmh5VVZfWkVZNUtVSGIzU2ZJQW1BYjdGYkEySzB6ZHhfb1ozMjBNeU9VR1dUNmFVNjhRNThONjk0NVRRR3pB?oc=5" target="_blank">MDG…
Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPdnFPYVR5dWs2NldldlpEbnVPLXZRdTJ6UGRjQmJENGtUNE9yWHdDMngzNmdSbmtvREV4NFFoajhzUEM1YlQ1bWJuazZpT0lVTEpobW9IOXBJdHJheVlOV0xfOGJaM2lNSXNjSFBuQzYyQkRNenAwOC1mUFpieUhxYXFqY3g5YXlSbV9INl…
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNS2lkWEJMeFViVkdGWHNFcUI3QXRNbExfMnNqUG1EUlB2UmpSam9FZ18xV05oYXh5MExObnM2MTh0OGttRlRYUDlBeHVKZzhEUEpBbWY1X3R0QXJCbjhmcVZha1QtS0FTcmJqdFNhOGFMd1dWbVBKV0JzbnZnLVNLR3BxM2lDWEE2S3ZQVD…
Will siRNA MASH Candidate Nomination with Suzhou Ribo Change Madrigal Pharmaceuticals' (MDGL) Narrative? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPc01BOExRR0xmR0JvWHR5UWFmVFhSQWpYSDhIZlVIdTZKd3JiaWtpemZtSGtsZmtVZ1gyUWcwUnY3MEVEWnVDM1V0VksxamJoV2ljQk95NGlveTJYR0I3MDBjby1VNGh4WlkwbGs2cGhDY19td3c2RFRJSVplVm41bTJpXzYtTGVEWVdOTz…
MDGL — Frequently Asked Questions
What is the current share price of Madrigal Pharmaceuticals, Inc. (MDGL)?
As of 2026-07-14 21:23 PDT, Madrigal Pharmaceuticals, Inc. (MDGL) trades at $536.86 on NasdaqGS. Its 52-week range is $289.88 to $602.83.
What is the market capitalisation of MDGL?
Madrigal Pharmaceuticals, Inc. (MDGL) has a market capitalisation of $12.38B on NasdaqGS.
What is the P/E ratio of MDGL?
MDGL trades at a trailing price-to-earnings (P/E) ratio of -39.74. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 20.38.
What is the return on equity (ROE) of MDGL?
MDGL has a return on equity (ROE) of -49.35%. Its return on capital employed (ROCE) is -31.61%.
Is MDGL a good stock to buy?
This page provides a data-driven analysis of Madrigal Pharmaceuticals, Inc. (MDGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.